Hikma Pharmaceuticals Plc - Company Profile
Powered by 
All the data and insights you need on Hikma Pharmaceuticals Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Hikma Pharmaceuticals Plc Strategy Report
- Understand Hikma Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Hikma Pharmaceuticals Plc (Hikma Pharmaceuticals) develops, manufactures, and markets a comprehensive range of branded, generic, and in-licensed products in oral and injectable dosage forms. The company classifies its business into three main reportable segments: Injectables, Generics and Branded. It develops, manufactures and commercializes a wide range of products in the US, Middle East and North Africa (MENA) and Europe.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focuses on the development and manufacture of high-quality medicines and enhancement of its products. It is developing products for the evolving needs of patients and healthcare professionals. It is developing a portfolio of biosimilars for the US and MENA markets. The company offers its products in higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology. In FY2023, the company spent US$149 million on research and development activities, which as a percentage of revenue, stood at 5.2%. In FY2023, it reported 107 regulatory filings, launched 157 new products and approval of 128 products. It has eight research and development center across the world.
Business Segments
Overview
Sells branded generics and in licensed new products in the MENA and other emerging markets. The segment has strong anti-infective franchise and increasing focus on cardiovascular, CNS and diabetes products. Some of the major products include Amoclan, Blopress, Prograf, Omnicef and Suprax. In FY2023, the segment launched 32 products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Sells non-injectable generic products in the US which include analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS and respiratory medicines. The company operates its Generics business through its US subsidiary, Hikma Pharmaceuticals USA Inc, formerly West-Ward Pharmaceuticals Corp. Its major products include amoxicillin, acetaminophen and caffeine, butalbital, buprenorphine, colchicine and fluticasone. Operates facilities in the US with a wide range of capabilities. In FY2023, the segment launched five products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Sells specialized generic injectable products globally, with state-of-the-art manufacturing facilities in Europe and the US. Product portfolio includes controlled substances, anti-infectives, and cardiovascular and cancer products. A few of the products include fentanyl, neostigmine, glycopyrrolate, nicardipine and thiotepa. In FY2023, the segment launched 25 products in MENA, 67 in Europe and ROW, and 28 in North America. The pipeline of injectables focuses on new therapeutic entities, differentiated delivery forms and more complex products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer